2.1B
People aged 60+ by 2050
Source: WHO
80%
Adults 65+ with chronic disease
Source: CDC
$7.1T
Global longevity market by 2025
Source: AARP
The Model
Science That Funds Itself.
Commerce That Proves the Science.
BICC operates a dual-engine model that is rare in biotech: a patented research platform that generates intellectual property, and a commercial longevity brand that generates the revenue to fund it. Neither engine can exist without the other.
Engine One
Institutional Biotech R&D
BICC's core research platform advances Extracellular Vesicle (EV) therapy — the next frontier of regenerative medicine. Our patented technology portfolio spans stem cell culture, exosome biologics, regenerative wound healing, cryopreservation, and immune cell therapies. This is the scientific moat that protects everything we build.
Engine Two
Commercial Longevity Platform
TSG is BICC’s commercial arm — a premium longevity nutraceutical brand with a network of distribution representatives including clinics and hospitals across Singapore, China, and Thailand, with planned expansion into Malaysia, Indonesia, and Vietnam. TSG generates the revenue that funds the R&D. The two engines are inseparable.
The Problem
2.1 Billion People
Running Out of Time.
By 2050, the global population aged 60 and above will double to 2.1 billion. The CDC reports that 80% of adults over 65 already live with at least one chronic disease. The economic cost of aging-related conditions is projected to reach $7.1 trillion annually by 2025.
This is not a healthcare problem. It is a civilizational problem. And it is the problem BICC was founded to solve — from the cellular level up.
The Platform
Extracellular Vesicle
Technology.
Extracellular Vesicles (EVs) are nano-sized biological particles secreted by stem cells that carry molecular cargo — proteins, lipids, and RNA — between cells. They are the communication system of regeneration.
BICC's patented EV platform delivers the regenerative signals of stem cells without the complexity of live cell transfer — a platform technology with applications spanning wound healing, neurodegeneration, metabolic disease, and aging.
The Network
A Global Network
Built for Scale.
Listing Partner & Capital Markets
Shineco Inc.
NASDAQ: SISI
Research Partner - Singapore
A*STAR
Research
Research Partner - China
Glabiolus Biomedical Tech.
Research
Strategic Investment Arm
Wealth Index Capital
Investment
Manufacturer - Japan
Kiyora Kikuchi
Manufacturer
Clinical Research Partner
Biotech & Biomedicine
(Shenyang)
Research
Headquartered in Singapore
Asia's Biotech Hub.
The World's Ambition.
Singapore's position as Asia's premier biomedical research hub — with world-class regulatory frameworks, deep capital market access, and proximity to the world's fastest-growing aging populations — makes it the ideal base for BICC's global ambitions.
3
Countries Active
3+
Planned Expansions
2026
NASDAQ Target
NASDAQ Pathway
Join Us at the Frontier
of Regenerative Medicine.
BICC is on a defined pathway to a NASDAQ listing in 2026. We are actively engaging institutional investors, strategic partners, and research collaborators who share our conviction that the science of longevity is the defining commercial opportunity of the next decade.